Literature DB >> 24240870

Temporal hemodynamic and histological progression in Sugen5416/hypoxia/normoxia-exposed pulmonary arterial hypertensive rats.

Michie Toba1, Abdallah Alzoubi, Kealan D O'Neill, Salina Gairhe, Yuri Matsumoto, Kaori Oshima, Kohtaro Abe, Masahiko Oka, Ivan F McMurtry.   

Abstract

We have investigated the temporal relationship between the hemodynamic and histological/morphological progression in a rat model of pulmonary arterial hypertension that develops pulmonary arterial lesions morphologically indistinguishable from those in human pulmonary arterial hypertension. Adult male rats were injected with Sugen5416 and exposed to hypoxia for 3 wk followed by a return to normoxia for various additional weeks. At 1, 3, 5, 8, and 13 wk after the Sugen5416 injection, hemodynamic and histological examinations were performed. Right ventricular systolic pressure reached its maximum 5 wk after Sugen5416 injection and plateaued thereafter. Cardiac index decreased at the 3∼5-wk time point, and tended to further decline at later time points. Reflecting these changes, calculated total pulmonary resistance showed a pattern of progressive worsening. Acute intravenous fasudil markedly reduced the elevated pressure and resistance at all time points tested. The percentage of severely occluded small pulmonary arteries showed a similar pattern of progression to that of right ventricular systolic pressure. These small vessels were occluded predominantly with nonplexiform-type neointimal formation except for the 13-wk time point. There was no severe occlusion in larger arteries until the 13-wk time point, when significant numbers of vessels were occluded with plexiform-type neointima. The Sugen5416/hypoxia/normoxia-exposed rat shows a pattern of chronic hemodynamic progression similar to that observed in pulmonary arterial hypertension patients. In addition to vasoconstriction, nonplexiform-type neointimal occlusion of small arteries appears to contribute significantly to the early phase of pulmonary arterial hypertension development, and plexiform-type larger vessel occlusion may play a role in the late deterioration.

Entities:  

Keywords:  neointimal occlusion; plexiform; vasoconstriction

Mesh:

Substances:

Year:  2013        PMID: 24240870      PMCID: PMC3920132          DOI: 10.1152/ajpheart.00728.2013

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  22 in total

1.  Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension.

Authors:  Y Fukumoto; T Matoba; A Ito; H Tanaka; T Kishi; S Hayashidani; K Abe; A Takeshita; H Shimokawa
Journal:  Heart       Date:  2005-03       Impact factor: 5.994

2.  Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension.

Authors:  Ken Ishikura; Norikazu Yamada; Masaaki Ito; Satoshi Ota; Mashio Nakamura; Naoki Isaka; Takeshi Nakano
Journal:  Circ J       Date:  2006-02       Impact factor: 2.993

3.  Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease.

Authors:  Fuhai Li; Wei Xia; Shuanghu Yuan; Ruopeng Sun
Journal:  Pediatr Cardiol       Date:  2008-10-25       Impact factor: 1.655

Review 4.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

5.  Pulmonary artery remodeling differs in hypoxia- and monocrotaline-induced pulmonary hypertension.

Authors:  R J van Suylen; J F Smits; M J Daemen
Journal:  Am J Respir Crit Care Med       Date:  1998-05       Impact factor: 21.405

6.  Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.

Authors:  Masahiko Oka; Noriyuki Homma; Laimute Taraseviciene-Stewart; Kenneth G Morris; Donatas Kraskauskas; Nana Burns; Norbert F Voelkel; Ivan F McMurtry
Journal:  Circ Res       Date:  2007-03-01       Impact factor: 17.367

7.  Rat pulmonary circulation after chronic hypoxia: hemodynamic and structural features.

Authors:  M Rabinovitch; W Gamble; A S Nadas; O S Miettinen; L Reid
Journal:  Am J Physiol       Date:  1979-06

Review 8.  Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure.

Authors:  Kurt R Stenmark; Barbara Meyrick; Nazzareno Galie; Wolter J Mooi; Ivan F McMurtry
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-09-11       Impact factor: 5.464

9.  Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension.

Authors:  Masahiko Oka; Vijaya Karoor; Noriyuki Homma; Tetsutaro Nagaoka; Eiko Sakao; Scott M Golembeski; Jennifer Limbird; Masatoshi Imamura; Sarah A Gebb; Karen A Fagan; Ivan F McMurtry
Journal:  Cardiovasc Res       Date:  2007-02-12       Impact factor: 10.787

10.  Comparison of cardiovascular effects of tiletamine-zolazepam, pentobarbital, and ketamine-xylazine in male rats.

Authors:  Dhanonjoy C Saha; Animita C Saha; Gautam Malik; Mark E Astiz; Eric C Rackow
Journal:  J Am Assoc Lab Anim Sci       Date:  2007-03       Impact factor: 1.232

View more
  41 in total

1.  Hemodynamics and right-ventricle functional characteristics of a swine carotid artery-jugular vein shunt model of pulmonary arterial hypertension: An 18-month experimental study.

Authors:  Ji Wu; Xiaoju Luo; Yuanyuan Huang; Yun He; Zhixian Li
Journal:  Exp Biol Med (Maywood)       Date:  2015-01-16

2.  Comparing pulmonary hypertension severity between rat strains suggests right ventricle NK cells are protective.

Authors:  Claudia Mickael; Michael H Lee; Sue Gu; Brian B Graham
Journal:  Cardiovasc Res       Date:  2019-03-15       Impact factor: 10.787

3.  Severe pulmonary arterial hypertensive rats are tolerant to mild exercise.

Authors:  Leslie A Hargett; Lauren J Hartman; April K Scruggs; Jared M McLendon; April K Haven; Natalie N Bauer
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

4.  Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension.

Authors:  Jared M McLendon; Sachindra R Joshi; Jeff Sparks; Majed Matar; Jason G Fewell; Kohtaro Abe; Masahiko Oka; Ivan F McMurtry; William T Gerthoffer
Journal:  J Control Release       Date:  2015-05-13       Impact factor: 9.776

5.  Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension.

Authors:  Rajkumar Savai; Hamza M Al-Tamari; Daniel Sedding; Baktybek Kojonazarov; Christian Muecke; Rebecca Teske; Mario R Capecchi; Norbert Weissmann; Friedrich Grimminger; Werner Seeger; Ralph Theo Schermuly; Soni Savai Pullamsetti
Journal:  Nat Med       Date:  2014-10-26       Impact factor: 53.440

6.  Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling.

Authors:  Nils P Nickel; Edda Spiekerkoetter; Mingxia Gu; Caiyun G Li; Hai Li; Mark Kaschwich; Isabel Diebold; Jan K Hennigs; Ki-Yoon Kim; Kazuya Miyagawa; Lingli Wang; Aiqin Cao; Silin Sa; Xinguo Jiang; Raymond W Stockstill; Mark R Nicolls; Roham T Zamanian; Richard D Bland; Marlene Rabinovitch
Journal:  Am J Respir Crit Care Med       Date:  2015-06-01       Impact factor: 21.405

7.  Aneurysm-type plexiform lesions form in supernumerary arteries in pulmonary arterial hypertension: potential therapeutic implications.

Authors:  Kaori Oshima; Edward S Crockett; Sachindra R Joshi; Jared M McLendon; Yuri Matsumoto; Ivan F McMurtry; Kohtaro Abe; Masahiko Oka
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-10-02       Impact factor: 5.464

Review 8.  A pro-con debate: current controversies in PAH pathogenesis at the American Thoracic Society International Conference in 2017.

Authors:  Wolfgang M Kuebler; Mark R Nicolls; Andrea Olschewski; Kohtaro Abe; Marlene Rabinovitch; Duncan Stewart; Stephen Y Chan; Nicholas W Morrell; Stephen L Archer; Edda Spiekerkoetter
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-06-07       Impact factor: 5.464

Review 9.  Update on novel targets and potential treatment avenues in pulmonary hypertension.

Authors:  John C Huetsch; Karthik Suresh; Meghan Bernier; Larissa A Shimoda
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-02       Impact factor: 5.464

Review 10.  Lung Circulation.

Authors:  Karthik Suresh; Larissa A Shimoda
Journal:  Compr Physiol       Date:  2016-03-15       Impact factor: 9.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.